Compare EEIQ & ALZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EEIQ | ALZN |
|---|---|---|
| Founded | 2017 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Medicinal Chemicals and Botanical Products |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.1M | 9.0M |
| IPO Year | 2021 | 2021 |
| Metric | EEIQ | ALZN |
|---|---|---|
| Price | $0.34 | $2.21 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $42.00 |
| AVG Volume (30 Days) | 66.8K | ★ 98.5K |
| Earning Date | 08-21-2025 | 12-11-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $9,358,301.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 44.99 | N/A |
| 52 Week Low | $0.23 | $1.88 |
| 52 Week High | $1.74 | $12.06 |
| Indicator | EEIQ | ALZN |
|---|---|---|
| Relative Strength Index (RSI) | 44.12 | 49.49 |
| Support Level | $0.31 | $2.03 |
| Resistance Level | $0.35 | $2.35 |
| Average True Range (ATR) | 0.03 | 0.18 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 84.23 | 51.47 |
EpicQuest Education Group International Ltd provides comprehensive education solutions for domestic and international students interested in university and college degree programs in the U.S., Canada, and the UK. In addition, the company has a recruiting relationship with the regional campuses of Miami University of Ohio, where it maintains residential facilities, a full-service cafeteria, recreational facilities, shuttle buses, and an office for the regional campuses that provides study abroad and post-study services for its students; these facilities are not owned, maintained, operated or are part of Miami University. Company operated in three primary reportable segments foreign language education (QHI), foreign language education (RIL) and the professional training programs.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.